TORONTO, Feb. 2, 2018 /PRNewswire/ – Avicanna Inc. (“Avicanna“) is pleased to announce that its Colombian subsidiary Sativa Nativa S.A.S. (“Sativa Nativa“) has been issued a psychoactive cannabis Cultivation license and a cannabis Derivatives Processing and Manufacturing license (collectively the “Licenses“) by the Colombian Ministry of Justice and Ministry of Health.
Sativa Nativa, located in Santa Marta, Colombia, is positioning itself to become a leader in the Latin American medical cannabis industry. Santa Marta offers an ideal location to cultivate cannabis due to its tropical climate complete with year-round 12 hour days of sunlight. These weather conditions can lead to significant cost advantages compared with cannabis grown in less hospitable climates such as Canada or Europe. With a team of cultivation and genetic specialists, including its founders Sergio Puerta and Jose Rafael Lopez, Sativa Nativa is in a strong position to excel in the Latin American cannabis industry. Leveraging the support of Avicanna’s senior scientific and executive teams, Sativa Nativa will have access to strategic know-how and proprietary advancements applicable to all phases of the cannabis growing process, including cultivation, analysis, extraction, and manufacturing. Avicanna will also aim to implement industry best practices while maintaining Good Manufacturing Practices (“GMP”) and Standard Operating Procedures (“SOP”) at Sativa Nativa’s facilities in Colombia. In addition, Sativa Nativa has been granted an exclusive license to produce, manufacture and distribute Avicanna’s proprietary brand of Pura Elements™ products within Colombia. As an Avicanna subsidiary, Sativa Nativa also has access to export opportunities through Avicanna’s global distribution network.
With over 30 years of combined experience in commercial scale cultivation and genetic development, Sativa Nativa’s founders provide a rare level of sophistication and experience in the emergent cannabis industry.
“Our sustainable cultivation practices focus on the biodynamic and organic production of cannabis, and working with the Avicanna team, we will focus on compliance with the highest global standards in each stage of production. We look forward to offering advanced medical cannabis solutions to the Colombian medical community.”
– Sergio Puerta, Chief Horticulture Officer, Sativa Nativa S.A.S.
As part of Avicanna’s international and vertically integrated business model, Sativa Nativa provides Avicanna with significant potential opportunities, including supply of high quality active pharmaceutical ingredients (APIs), distribution in the Colombian market, proximity to other Latin American markets, and access to a diverse portfolio of cannabis genetics.
“We are delighted by this endorsement of the Colombia health